Literature DB >> 29417613

Decitabine improves response rate and prolongs progression-free survival in older patients with newly diagnosed acute myeloid leukemia and with monosomal karyotype: A subgroup analysis of the DACO-016 trial.

Agnieszka Wierzbowska1, Ewa Wawrzyniak1, Agnieszka Pluta1, Tadeusz Robak1, Grzegorz J Mazur2, Anna Dmoszynska3, Jaroslav Cermak4, Albert Oriol5, Daniel Lysak6, Chris Arthur7, Margaret Doyle8, Liang Xiu9, Farhad Ravandi10, Hagop M Kantarjian10.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29417613     DOI： 10.1002/ajh.25062

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  6 in total

Review 1.  Patterns of mutations in TP53 mutated AML.

Authors:  John S Welch
Journal:  Best Pract Res Clin Haematol       Date:  2018-09-20       Impact factor: 3.020

2.  Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience.

Authors:  Sara Pepe; Emilia Scalzulli; Gioia Colafigli; Alessio Di Prima; Daniela Diverio; Marco Mancini; Roberto Latagliata; Maurizio Martelli; Robin Foà; Massimo Breccia
Journal:  Ann Hematol       Date:  2020-08-19       Impact factor: 3.673

3.  Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia.

Authors:  Heiko Becker; Dietmar Pfeifer; Gabriele Ihorst; Milena Pantic; Julius Wehrle; Björn H Rüter; Lars Bullinger; Björn Hackanson; Ulrich Germing; Andrea Kuendgen; Uwe Platzbecker; Konstanze Döhner; Arnold Ganser; Anne Hagemeijer; Pierre W Wijermans; Hartmut Döhner; Justus Duyster; Michael Lübbert
Journal:  Ann Hematol       Date:  2020-06-06       Impact factor: 3.673

4.  Diallyl disulfide down-regulates calreticulin and promotes C/EBPα expression in differentiation of human leukaemia cells.

Authors:  Jing Sun; Hongxiang Mu; Jia Yu; Linwei Li; Hongxia Yan; Guoqing Li; Hui Tan; Nanyang Yang; Xiaoyan Yang; Lan Yi
Journal:  J Cell Mol Med       Date:  2018-11-05       Impact factor: 5.310

Review 5.  The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia.

Authors:  Valeria Santini; Michael Lübbert; Agnieszka Wierzbowska; Gert J Ossenkoppele
Journal:  Adv Ther       Date:  2021-11-16       Impact factor: 3.845

Review 6.  BCL-2 as therapeutic target for hematological malignancies.

Authors:  Guilherme Fleury Perini; Glaciano Nogueira Ribeiro; Jorge Vaz Pinto Neto; Laura Tojeiro Campos; Nelson Hamerschlak
Journal:  J Hematol Oncol       Date:  2018-05-11       Impact factor: 17.388
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.